NCT05264025

Fexofenadine in Patients With Active Rheumatoid Arthritis

Fexofenadine as Adjunct to Standard Rheumatoid Therapy in Patients With Active Rheumatoid

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: October 6 University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying fexofenadine mediated inhibition of TNF-α signalling

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	Fexofenadine	tablet
DRUG	Placebo	tablet

Timeline

• Start date: 2022-06-01
• Primary completion: 2025-12-01
• Completion: 2026-01-01
• First posted: 2022-03-03
• Last updated: 2025-07-31

Locations

2 sites across 1 country: Egypt